Article
Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?
Cancer biology & therapy - 2 Dec 2021
Sutton Thomas L, Grossberg Aaron, Ey Frederick, O'Reilly Eileen M, Sheppard Brett C
Abstract excerpt
Metastatic pancreatic adenocarcinoma (PDAC) is a rapidly lethal disease, with less than half of patients surviving 12 months, and 5-year survival approximately 3%. These outcomes are in large part due to a lack of effective medical and surgical therapies for metastatic PDAC. Herein, we present the case of a patient with oligometastatic liver recurrence of BRCA2-mutated PDAC following a curative-intent resection....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.